Table 2. Characteristics of the twenty HCV chronic patients longitudinally followed during treatment course.

Patient ID	Age/Sex	HCV Genotype	Plasma HCVa	ALT (UxL-1)	AST (Ux L-1)	MDC cluster group	PBMC Viabilityb	CD8+ Ag-specifc T cells			Therapy Outcome
								HCV		CEF
								%c	Proteinsd	%c
P47	50/M	2b	6.35	126	60	CP-N	≥95%	ND	ND	ND	SVR
P55	54/M	1a	6.07	130	72	CP-N	≥95%	0.32	3	0.05	SVR
P64	52/M	1a	6.87	48	37	CP-N	≥95%	0.01	1	0.65	NR
P69	45/M	1a	6.53	88	40	CP-N	≥95%	0.32	3	0.23	SVR
P70	49/F	1a	6.43	40	37	CP-N	≥95%	2.04	2	2.04	SVR
P71	45/F	1a	5.29	62	54	CP-N	≥95%	0.01	1	1.54	NR
P74	50/F	1a	7.13	22	23	CP-N	low	ND	ND	ND	SVR
P75	P75	1a	6.60	52	48	CP-N	low	ND	ND	ND	SVR
P76	68/M	1a/b	6.92	43	45	CP-N	≥95%	0.73	4	0.67	NR
P77	43/M	1	6.16	222	115	CP-N	low	ND	ND	ND	SVR
P78	52/M	2	6.46	186	160	CP-N	low	ND	ND	ND	SVR
P79	33/F	2	6.53	49	33	CP-N	≥95%	ND	ND	ND	SVR
P80	51/F	2b	6.05	117	80	CP-N	≥95%	ND	ND	ND	SVR
P82	45/M	3	4.01	81	40	CP-N	low	ND	ND	ND	SVR
P83	44/M	3a	5.18	39	27	CP-N	≥95%	ND	ND	ND	SVR
P48	43/M	1a	5.85	42	34	CP-D	≥95%	0.01	1	0.15	NR
P49	60/F	1b	5.82	91	80	CP-D	≥95%	0.03	1	0.31	NR
P60	49/M	1a	6.23	178	71	CP-D	≥95%	0.01	2	0.03	SVR
P65	44/F	1b	6.16	43	60	CP-D	≥95%	0.08	1	0.36	NR
P84	43/M	3a	5.81	172	134	CP-D	≥95%	ND	ND	ND	NR

^alog₁₀ IU/ml.

^bBy trypan blue count; visits during and following treatment.

^cFrequencies are total cytokine-producing (IFN-γ, IL-2, TNFα) and degranulating (CD107a⁺) cells out of the CD8⁺ memory subset at pre-treatment. All positive responses to HCV pools were summed to determine the total antigen-specific response within the memory peripheral blood T cell populations. Due to HCV peptide reagent availability, only genotype 1 patients could be stimulated. ND: not determined.

^dNumber of HCV proteins detected by CD8⁺ T cells.